Phase I and pharmacodynamic study of the oral MEK inhibitor CI-1040 in patients with advanced malignancies

Journal of Clinical Oncology

Volumn 23, Issue 23, 2005, Pages 5281-5293

  LoRusso, Patricia M ^a   Adjei, Alex A ^a   Varterasian, Mary ^a   Gadgeel, Shirish ^a   Reid, Joel ^a   Mitchell, David Y ^a   Hanson, Lorelei ^a   DeLuca, Pamela ^a   Bruzek, Laura ^a   Piens, Jill ^a   Asbury, Peggy ^a   Van Becelaere, Keri ^a   Herrera, Roman ^a   Sebolt Leopold, Judith ^a   Meyer, Mark B ^a  

^a KARMANOS CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 (2 CHLORO 4 IODOANILINO) N CYCLOPROPYLMETHOXY 3,4 DIFLUOROBENZAMIDE; ANTINEOPLASTIC AGENT; DRUG METABOLITE; MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR; MITOGEN ACTIVATED PROTEIN KINASE KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; PD 0184264; UNCLASSIFIED DRUG; 2-(2-CHLORO-4-IODOPHENYLAMINO)-N-CYCLOPROPYLMETHOXY-3,4-DIFLUOROBENZAMIDE; BENZAMIDE DERIVATIVE; ENZYME INHIBITOR; MAP2K1 PROTEIN, HUMAN; MAP2K2 PROTEIN, HUMAN; PROTEIN KINASE (CALCIUM,CALMODULIN);

ADULT; ADVANCED CANCER; AGED; AREA UNDER THE CURVE; ARTICLE; ASTHENIA; CANCER INHIBITION; CANCER TISSUE; CLINICAL TRIAL; COLORECTAL CANCER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE DURATION; DISEASE SEVERITY; DRUG ABSORPTION; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG STRUCTURE; FEMALE; HUMAN; INCIDENCE; KIDNEY CANCER; LEUKOCYTE; LIPID DIET; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MAXIMUM TOLERATED DOSE; MELANOMA; NAUSEA; NEUTROPENIA; PANCREAS CANCER; PATIENT SELECTION; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RASH; SINGLE DRUG DOSE; STEADY STATE; TREATMENT RESPONSE; VOMITING; BLOOD; DRUG ANTAGONISM; METABOLISM; METASTASIS; MIDDLE AGED; NEOPLASM; ORAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, ORAL; ADULT; AGED; AGED, 80 AND OVER; BENZAMIDES; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; ENZYME INHIBITORS; FEMALE; HUMANS; MALE; MAP KINASE KINASE 1; MAP KINASE KINASE 2; MAXIMUM TOLERATED DOSE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASMS; TREATMENT OUTCOME;

EID: 23944439944     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2005.14.415     Document Type: Article

References (21)

1. Anderson N, Maller J, Tonks N, et al: Requirement for integration of signals from two distinct phosphorylation pathways for activation of MAP kinase. Nature 343:651-653, 1990
2. Seger R, Ahn NG, Posada J, et al: Purification and characterization of mitogen-activated protein kinase activator(s) from epidermal growth factor-stimulated A431 cells. J Biol Chem 267:14373-14381, 1992
3. Cowley S, Paterson H, Kemp P, et al: Activation of MAP kinase kinase is necessary and sufficient for PC12 differentiation and for transformation of NIH 3T3 cells. Cell 77:841-852, 1994
4. Mansour S, Matten W, Hermann A, et al: Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265:966-969, 1994
5. Hoshino R, Chatani Y, Yamori T, et al: Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors. Oncogene 18:813-822, 1999
6. Sebolt-Leopold JS: Development of anti-cancer drugs targeting the MAP kinase pathway. Oncogene 19:6594-6599, 2000
7. Sebolt-Leopold J, Van Becelaere K, Dudley D, et al: Blockade of the MAP kinase pathway retards growth of murine and human tumors in vivo. Proc Am Assoc Cancer Res 40:40, 1999 (abstr 785)
8. Sebolt-Leopold JS, Dudley DT, Herrera R, et al: Blockade of the MAP kinase pathway suppresses growth of colon tumors in vivo. Nat Med 5:810-816, 1999
9. Ohren J, Chen H, Pavlovsky A, et al: Structures of human MAP kinase kinase 1 (MEK 1) and MEK2 describe novel noncompetitive kinase inhibition. Nat Struct Mol Biol 11:1192-1197, 2004
10. Pages G, Lenormand P, L'Allemain G, et al: Mitogen-activated protein kinases p42-mapk and p44-mapk are required for fibroblast proliferation. Proc Natl Acad Sci U S A 90:8319-8323, 1993
11. Allen LF, Sebolt-Leopold JS, Meyer MB: CI-1040 (PD-184,352), a targeted signal transduction inhibitor of MEK (MAPKK). Semin Oncol 30:105-116, 2003
12. Sebolt-Leopold J, Herrera R: Targeting the mitogen-activated kinase cascade to treat cancer. Nat Rev Cancer 4:937-947, 2004
13. Ratain MJ: Body-surface area as a basis for dosing of anticancer agents: Science, myth, or habit? J Clin Oncol 16:2297-2298, 1998
14. Schakel S, Sievert Y, Buzzard I: Sources of data for developing and maintaining a nutrient database. J Am Diet Assoc 88:1268-1271, 1988
15. Sebolt-Leopold JS, Van Becelaere K, Hook K, et al: Methods in Molecular Medicine. Totowa, NJ, Humana Press Inc. 2003
16. Smalley K: A pivotal role for ERK in the oncogenic behaviour of malignant melanoma? Int J Cancer 104:527-532, 2003
17. Dy G, Haluska P, Adjei A: Novel pharmacological agents in clinical development for solid tumors. Expert Opin Investig Drugs 10:2059-2088, 2001
18. Hidalgo M, Siu LL, Nemunaitis J, et al: Phase I and pharmacologic study of OSI-774, an epidermal growth factor receptor tyrosine kinase inhibitor, in patients with advanced solid malignancies. J Clin Oncol 19:3267-3279, 2001
19. Herbst RS, Maddox AM, Rothenberg ML, et al: Selective oral epidermal growth factor receptor tyrosine kinase inhibitor ZD1839 is generally well-tolerated and has activitiy in non-small-cell lung cancer and other solid tumors: Results of a phase I trial. J Clin Oncol 20:3815-3825, 2002
20. Rinehart J, Adjei A, LoRusso P, et al: Multicenter phase II study of the oral MEK inhibitor, CI-1040, in patients with advanced non-small cell lung, breast, colon, and pancreatic cancer. J Clin Oncol 22:4456-4462, 2004
21. LoRusso P, Krishnamurthy S, Rinehart J, et al: A phase 1-2 clinical study of a second generation oral MEK inhibitor, PD 0325901 in patients with advanced cancer. Proc Am Soc Clin Oncol 23:194s, 2005 (abstr 3011)